Dealings in Securities by an Executive Director and Executive Officer of AngloGold Ashanti plc
LONDON & DENVER & JOHANNESBURG — AngloGold Ashanti plc (the 'Company') (NYSE: AU; JSE: ANG) announces that an Executive Director, Alberto Calderon, and an Executive Officer of the Company, Richard Jordinson, have dealt in securities of the Company. A portion of the shares received by Alberto Calderon have been sold to satisfy related taxes as detailed below. The shares received by Richard Jordinson, who will retire as Chief Operating Officer of the Company and member of the Executive Committee with effect from 1 June 2025 after 13 years in senior management positions in the Company, have been sold, in part to satisfy related taxes.
Article content
Article content
Name of Executive Director
Alberto Calderon
Name of Company
AngloGold Ashanti plc
Date of transaction
13 May 2025
Nature of transaction
Off-market receipt of vested shares under the 2023 Deferred Share Plans (DSP)
Class of security
Ordinary shares
Number of securities
80,296
Price per security
Nil
Nature and extent of interest
Direct, Beneficial
Article content
Name of Executive Director
Alberto Calderon
Name of Company
AngloGold Ashanti plc
Date of transaction
13 May 2025
Nature of transaction
On-market sale of shares to fund tax liability in relation to DSP awards
Class of security
Ordinary shares
Number of securities sold
40,148
Price per security
US$40.8845 1
Value of transaction (excluding fees)
US$1,641,431.37
Nature and extent of interest
Direct, Beneficial
Article content
(1)
Weighted average price. These shares were sold in multiple transactions at prices ranging from US$40.8792 to US$40.9248 inclusive.
Article content
Name of Executive Officer
Richard Jordinson
Name of Company
AngloGold Ashanti plc
Date of transaction
13 May 2025
Nature of transaction
Off-market receipt of vested shares under the 2023 Deferred Share Plans (DSP)
Class of security
Ordinary shares
Number of securities
38,346
Price per security
Nil
Nature and extent of interest
Direct, Beneficial
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media
Andrea Maxey
+61 08 9435 4603 / +61 400 072 199
amaxey@aga.gold
Article content
General inquiries
media@anglogoldashanti.com
Article content
Investors
Andrea Maxey
+61 08 9435 4603 / +61 400 072 199
amaxey@aga.gold
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
21 minutes ago
- National Post
Altius Completes Sale of 2/3 of its Silicon Gold 1.5% NSR to Franco-Nevada
Article content ST. JOHN'S, Newfoundland and Labrador — Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) Altius Minerals Corporation ('Altius') is pleased to announce that Altius Royalty Corporation ('ARC'), a wholly-owned subsidiary of Altius, has completed the sale of a 1% NSR royalty covering the Silicon and Merlin gold deposit discoveries in Nevada ('1% NSR Silicon Royalty') to a wholly owned subsidiary of Franco-Nevada Corporation ('Franco-Nevada') (TSX & NYSE: FNV) ('The Transaction'), pursuant to a royalty purchase agreement entered into by ARC and Franco-Nevada (the 'Agreement'). ARC will continue to hold a remaining 0.5% NSR royalty interest in Silicon (recently renamed to the Arthur Gold Project by AngloGold Ashanti plc ('AGA') as a long-term component of its diversified portfolio. Article content Article content The purchase price for the 1% NSR Silicon Royalty interest is US$ 275 million (~ C$ 375 million) comprised of US$ 250 million in upfront cash paid at closing and a further payment of US $25 million in cash payable upon the conclusion of an ongoing arbitration process that confirms the area subject to the royalty under final award to be consistent with Altius's interpretation of the partial award of the arbitration tribunal that was issued and reported on earlier this year. Article content The Board of Directors of Altius has received a fairness opinion from Cormark Securities Inc. which opinion concluded that, based upon and subject to the assumptions made, procedures followed, matters considered, limitations and qualifications set out therein, the consideration to be received by ARC pursuant to the Transaction is fair, from a financial point of view, to ARC. Article content Brian Dalton, CEO of Altius commented, 'We are pleased to partner with Franco-Nevada on this royalty, which encompasses AGA's world-class Silicon and Merlin gold deposit discoveries in Nevada, as well as extensive areas of prospective surrounding land. The Transaction crystallizes significant value for shareholders while further demonstrating the ability of Altius's Project Generation business to amplify the return profile of its overall royalty investment portfolio. The decision to retain a third of our Silicon royalty interest also provides continuing growth exposure to this emerging gold district, while confirming the addition of precious metals as a long-term, well-balanced component of our shareholder's diversified royalty portfolio. We now look forward to the ability to explore a wider set of capital allocation and deployment opportunities, facilitated by a considerably strengthened balance sheet and liquidity profile, and to further growing shareholder value.' Article content Anticipated Benefits to Altius Shareholders Article content Capital Allocation Opportunities Article content Cash, after taxes and fees, expected to increase to more than C$ 360 million (assumes up front and further payment proceeds from this Transaction and also from the recent acquisition of Orogen Royalties Inc. by Triple Flag Precious Metals Corp.) Total liquidity increased to more than C$ 540 million (including C$ 116 million available under a revolving credit facility and C$ 62.5 million potentially available under an accordion feature) Creates enhanced flexibility to evaluate external M&A opportunities while limiting equity level dilution of existing assets and the embedded growth potential of our portfolio Improves ability to opportunistically increase per share exposure to existing royalty interests through share repurchases Article content Retained Royalty Exposure Article content Continuing optionality exposure to gold resource growth 1 from current ~16 Moz resource estimate at the Arthur Gold Project, as AGA continues aggressive exploration and delineation drilling programs and the reporting of encouraging results Achieves rebalance of commodity exposures while confirming precious metals and another tier-1 quality royalty as components of Altius's long-term, diversified portfolio. Article content For further information, please see the updated Altius corporate presentation posted to the website at 1 See Expanded Silicon Project Update presentation Financial and Legal Advisors Cormark Securities Inc. is acting as financial advisor to Altius. Stikeman Elliott LLP is acting as legal counsel to Altius and ARC. Article content About Altius Article content Altius's strategy is to create per share growth through a diversified portfolio of royalty assets that relate to long life, high margin operations. This strategy further provides shareholders with exposures that are well aligned with global growth trends including increasing electricity based market share within energy usage, global infrastructure build and refurbishment growth, increased EAF based steelmaking, steadily increasing agricultural fertilizer requirements and the enhanced appetite for financial asset diversification through precious metals ownership. These macro-trends each hold the potential to cause higher demand for many of Altius's commodity exposures including potash, high purity iron ore, renewable energy, base metals, and gold . In addition, Altius runs a successful Project Generation business that originates mineral projects for sale to developers in exchange for royalties and that has a demonstrated track record of driving outsized direct returns from its overall royalty investment portfolio. Altius has 46,315,304 common shares issued and outstanding that are listed on Canada's Toronto Stock Exchange. It is a member of both the S&P/TSX Small Cap and S&P/TSX Global Mining Indices and the S&P/TSX Canadian Dividend Aristocrats Index. Article content This news release contains forward-looking information. The statements are based on reasonable assumptions and expectations of management and Altius provides no assurance that actual events will meet management's expectations. The information in this news release about the any anticipated benefits of the transaction to Altius Shareholders, timing and results of the ongoing arbitration process in respect of the Silicon royalty and possibility of ARC being paid contingent consideration of US$25 million following conclusion thereof, and any other information herein that is not a historical fact may be forward looking information. In certain cases, forward-looking information may be identified by such terms as 'anticipates', 'believes', 'could', 'estimates', 'expects', 'may', 'shall', 'will', or 'would'. Although Altius believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those projected. Readers should not place undue reliance on forward-looking information. Altius does not undertake to update any forward-looking information contained herein except in accordance with securities regulations. Article content Article content Article content Article content Article content Contacts Article content For further information, please contact: Flora Wood Article content Email: Article content Article content Article content
CTV News
5 hours ago
- CTV News
Chartwell purchases 6 retirement and seniors' communities for $432 million
Several senior and retirement communities will be purchased by a major housing provider as it expand its footprint across Ontario for nearly half a billion dollars. Chartwell Retirement Residences says it will purchase six senior and retirement communities, with a total of 1,024 suites, for $432 million across London, Waterloo, Dorchester and Mississauga, according to a news release. 'This was a great addition, certainly to our portfolio, we are very happy to expand in the very strong southwestern Ontario market,' Vlad Volodarski, chief executive officer of Chartwell told BNN Bloomberg in a Wednesday interview. 'We did not have a lot of presence in the London market in particular, and this portfolio gave us the opportunity to expand there.' Statistics Canada states there were about 7.6 million seniors (residents aged 65 and older) in Canada, representing 18.9 per cent of the total population in 2023. The agency estimates by 2030, seniors could represent from 21.4 per cent to 23.4 per cent of the total population. The purchased properties are Riverstone, Richmond Woods and Longworth in London, Dorchester Terrace in Dorchester, Westhill in Waterloo and Erinview in Mississauga. Chartwell will pay $416.2 million for the properties while Dorchester Terrace townhomes will be paid on competition of construction for $15.8 million. Construction is expected to be completed in the fourth quarter of 2026. 'We've announced over the last probably 18 months, over $2 billion worth of acquisitions, and we continue to look for opportunities to add high quality properties to our portfolio going forward, to take advantage and to serve more seniors across the country, because the demand continues to grow,' said Volodarski. Chartwell's revenue was $661 million with a net income of $49.5 million, according to an annual report. The company owns 200 properties, serves over 25,000 seniors and employs 16,000 people across Ontario, Quebec, Alberta and British Columbia, according to its website. The acquisition includes additional land at the Erinview site, with the potential to develop an additional 140 suites. The purchase price will be settled by assuming in-place debt of $232.7 million, a majority CMHC-insured, and in part from proceeds of already planned CMHC financings this year of $240 million.
CTV News
5 hours ago
- CTV News
Five years after COVID, pharma shares languish in U.S. policy limbo
A vial of the Phase 3 Novavax coronavirus vaccine is prepared for a trial at St. George's University hospital in London on Oct. 7, 2020. (Alastair Grant / AP Photo) MILAN — Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived 'most-favored-nation' drug pricing rules in the lucrative U.S. market and potential 200 per cent tariffs on pharma imports into the U.S. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved. At 15.9 times forward earnings, healthcare trades 11 per cent below its long-term average and 20 per cent below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. 'We've moved from cautious optimism to cautious pessimism,' said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. 'Valuations have gotten even cheaper, but for a reason,' she added, referring to intensifying U.S. policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs. 'Armageddon scenario' Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. 'These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely,' he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total US$7.2 billion, down 41 per cent from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up - yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. Catalyst needed Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unraveled under political pressure from Washington and investors' love of Big Tech. Over the past three years, U.S. healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27 per cent discount, from parity to the S&P in 2023. 'Markets don't like uncertainty, and that shows up in valuations,' said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. 'Being cheap isn't necessarily a reason to buy. You need a catalyst.' For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference. Yoon, who has typically been underweight Big Pharma due to patent expiry risks, notes smaller, innovative firms are becoming profitable. 'We're seeing companies go from unprofitable to very profitable,' he said, citing Alnylam and Penumbra as examples he owns. 'Historically, that's been a very good time to own healthcare stocks.' LFG+ZEST's Conca, who favors U.S. names like Abbott, Edwards Lifesciences, and AbbVie, along with Sanofi and Recordati in Europe, said interest rate cuts could be a major catalyst. Out of the woods? In Europe, healthcare is even cheaper than U.S. pharma, trading at 14.3 times forward earnings. A 55 per cent drop in shares of Novo Nordisk in the last year, related in part to concerns over competition in obesity drugs, along with tariff-driven production shifts to the U.S., has weighed on valuations. 'The sector will adapt,' wrote Arnaud Cadart, healthcare analyst at France's CIC Market Solutions. But that will come 'at the cost of rebalancing its revenues and probably transforming its organizations.' AstraZeneca, for example, has unveiled a US$50 billion U.S. investment. For now, the sector remains in limbo: cheap, but lacking enough visibility to trigger a broad re-rating. 'Healthcare has endured a lot of pain,' said J.P. Morgan's Aliaga. 'We're not sure if that pain is done, but the worst is likely over, given how extreme the exodus has been.' --- Reporting by Danilo Masoni; Editing by Amanda Cooper and Jane Merriman
